Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia

OBJECTIVES: Friedreich ataxia (FRDA) is a rare disorder with progressive neurodegeneration and cardiomyopathy. Luvadaxistat (also known as TAK‐831; NBI‐1065844), an inhibitor of the enzyme d‐amino acid oxidase, has demonstrated beneficial effects in preclinical models relevant to FRDA. This phase 2,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Norton, Jonathan, Xu, Lin, DeMartinis, Nicholas, Sen, Rohini, Shah, Ankit, Farmer, Jennifer, Lynch, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164851/
https://www.ncbi.nlm.nih.gov/pubmed/34018342
http://dx.doi.org/10.1002/acn3.51373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164851/
https://www.ncbi.nlm.nih.gov/pubmed/34018342
http://dx.doi.org/10.1002/acn3.51373

Ejemplares similares